Enliven Therapeutics, Inc. ("Enliven" or the "Company"), a precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today provided a corporate update on the close of an $85 million Series B financing, additions to the Board of Directors, and expansion of the Company's leadership team.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven's discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. For more information, please visit EnlivenTherapeutics.com.

Enliven Therapeutics Provides Corporate Update On Financing, Expansion Of Board And Leadership Team

Description

Company Information

Enliven Therapeutics Provides Corporate Update On Financing, Expansion Of Board And Leadership Team

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information